A mono-centre, non-comparative clinical trial on the inhibition of ovulation with LNG POP (Levonorgestrel tablet, 0.135 mg) during three 28-day cycles with continuous treatment and intentional intake errors

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521236-12-00

Acronym

1460lng24ct

Enrollment

Registered

2025-06-05

Start date

2025-07-02

Completion date

Unknown

Last updated

2025-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Investigation of ovulation inhibition after intentional IMP intake errors for indication of contraception

Brief summary

Ovulation under treatment (Ovulation during treatment is defined as a Hoogland-Skouby score (HSS) 5 or 6 in combination with fulfilment of Landgren criterion (P concentration >16.0 nmol/l during at least 5 consecutive days)

Interventions

DRUGLNG-POP Levonorgestrel 0.135 mg Tablet

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Ovulation under treatment (Ovulation during treatment is defined as a Hoogland-Skouby score (HSS) 5 or 6 in combination with fulfilment of Landgren criterion (P concentration >16.0 nmol/l during at least 5 consecutive days)	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026